BioArctic says China approves Leqembi subcutaneous autoinjector for initiation treatment

PUBT · 2d ago
BioArctic says China approves Leqembi subcutaneous autoinjector for initiation treatment
  • BioArctic: China’s NMPA cleared Leqembi subcutaneous autoinjector for initiation treatment in early Alzheimer’s disease.
  • Launch in China planned during Eisai’s fiscal 2026, ending March 31, 2027.
  • Regimen set at 500 mg once weekly via two 250 mg injections, offering at-home dosing versus biweekly IV infusions.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. BioArctic AB published the original content used to generate this news brief via Cision (Ref. ID: 20260903:BIT:5811:0) on September 03, 2026, and is solely responsible for the information contained therein.